REPL

MKT CAP:$197M

Replimune Group, Inc.

Market Cap

$197M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.42-$6.48 (-72.75%)

Apr 24, 2026

Company Details

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune syste...

CEO

Sushil Patel

IPO Date

Jul 20, 2018

Website

www.replimune.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$315M

EPS (Diluted)

-$3.58

Free Cash Flow

-$283M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2026

Feb 3, 2026

$0EPS -$0.77

Q2 2026

Nov 6, 2025

$0EPS -$0.90

Q1 2026

Aug 7, 2025

$0EPS -$0.95

FY 2025

May 22, 2025

$0EPS -$3.07

Q4 2025

May 22, 2025

$0EPS -$0.96

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$0	$0	-$32M
Q1 23	$0	$0	-$41M
Q2 23	$0	$0	-$42M
Q3 23	$0	$0	-$42M
Q4 23	$0	$0	-$53M
Q1 24	$0	$0	-$56M
Q2 24	$0	$0	-$64M
Q3 24	$0	$0	-$57M
Q4 24	$0	$0	-$59M
Q1 25	$0	$0	-$57M
Q2 25	$0	$0	-$59M
Q3 25	$0	$0	-$66M
Q4 25	$0	-$848.0K	-$80M
Q1 26	$0	$0	-$90M
Q2 26	$0	$0	-$84M
Q3 26	$0	$0	-$72M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$23M	-$24M
Q1 23	-$33M	-$35M
Q2 23	-$33M	-$34M
Q3 23	-$29M	-$29M
Q4 23	-$33M	-$33M
Q1 24	-$49M	-$49M
Q2 24	-$44M	-$45M
Q3 24	-$47M	-$49M
Q4 24	-$46M	-$48M
Q1 25	-$49M	-$51M
Q2 25	-$39M	-$41M
Q3 25	-$51M	-$53M
Q4 25	-$54M	-$55M
Q1 26	-$77M	-$80M
Q2 26	-$81M	-$83M
Q3 26	-$66M	-$66M

Capital Expenditures

Quarter	CapEx
Q4 22	$1M
Q1 23	$1M
Q2 23	$396.0K
Q3 23	$555.0K
Q4 23	$251.0K
Q1 24	$449.0K
Q2 24	$2M
Q3 24	$2M
Q4 24	$2M
Q1 25	$2M
Q2 25	$2M
Q3 25	$2M
Q4 25	$1M
Q1 26	$3M
Q2 26	$1M
Q3 26	$135.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+44.2%
Q1 23	—	+49.3%
Q2 23	—	+42.2%
Q3 23	—	+40.2%
Q4 23	—	+65.7%
Q1 24	—	+36.1%
Q2 24	—	+53.5%
Q3 24	—	+35.8%
Q4 24	—	+10.9%
Q1 25	—	+3.1%
Q2 25	—	-7.7%
Q3 25	—	+16.8%
Q4 25	—	+36.0%
Q1 26	—	+57.6%
Q2 26	—	+43.1%
Q3 26	—	+8.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	—
Q1 23	$7M	—
Q2 23	$7M	—
Q3 23	$0	—
Q4 23	$7M	—
Q1 24	$9M	—
Q2 24	$9M	—
Q3 24	$0	—
Q4 24	$0	—
Q1 25	$9M	—
Q2 25	$9M	—
Q3 25	$9M	—
Q4 25	$8M	—
Q1 26	$9M	—
Q2 26	$8M	—
Q3 26	$7M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$22M	—	—
Q1 23	$29M	$11M	—
Q2 23	$29M	$13M	—
Q3 23	$30M	—	—
Q4 23	$38M	—	—
Q1 24	$40M	—	—
Q2 24	$49M	—	—
Q3 24	$43M	—	—
Q4 24	$43M	—	—
Q1 25	$43M	—	—
Q2 25	$43M	—	—
Q3 25	$48M	—	—
Q4 25	$55M	—	$25M
Q1 26	$58M	—	—
Q2 26	$58M	—	$26M
Q3 26	$53M	—	$19M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$106M	$290M	$396M
Q1 23	$112M	$283M	$395M
Q2 23	$89M	$283M	$372M
Q3 23	$207M	$410M	$616M
Q4 23	$147M	$437M	$583M
Q1 24	$106M	$433M	$539M
Q2 24	$76M	$421M	$497M
Q3 24	$98M	$369M	$466M
Q4 24	$74M	$346M	$421M
Q1 25	$152M	$317M	$469M
Q2 25	$113M	$319M	$432M
Q3 25	$172M	$364M	$537M
Q4 25	$111M	$373M	$484M
Q1 26	$97M	$306M	$403M
Q2 26	$102M	$221M	$324M
Q3 26	$123M	$146M	$269M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	47M	-9.5%	+1.7%
Q1 23	54M	+14.5%	+4.4%
Q2 23	55M	+1.0%	+5.2%
Q3 23	58M	+5.6%	+10.6%
Q4 23	57M	-2.0%	+19.7%
Q1 24	66M	+17.1%	+22.4%
Q2 24	67M	+0.3%	+21.6%
Q3 24	67M	+0.1%	+15.2%
Q4 24	61M	-7.8%	+8.4%
Q1 25	69M	+12.7%	+4.2%
Q2 25	79M	+13.6%	+18.0%
Q3 25	83M	+6.3%	+25.3%
Q4 25	81M	-3.5%	+31.2%
Q1 26	92M	+13.6%	+32.3%
Q2 26	92M	+0.4%	+17.0%
Q3 26	92M	+0.3%	+10.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	$0	206
Q1 23	$0	206
Q2 23	$0	206
Q3 23	$0	206
Q4 23	$0	284
Q1 24	$0	284
Q2 24	$0	284
Q3 24	$0	284
Q4 24	$0	331
Q1 25	$0	331
Q2 25	$0	331
Q3 25	$0	331
Q4 25	$0	479
Q1 26	$0	479
Q2 26	$0	479
Q3 26	$0	479

Revenue / Employee